Note 12 - Segment and Geographic Information - Operating Segment Reconciliation to Net Income (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net sales		$ 219,863	$ 193,484	$ 161,651
Cost of sales		68,962	66,435	56,755
Gross profit		150,901	127,049	104,896
Research and development expense		15,650	16,966	13,294
Restructuring expense		0	485	3,107
Net income		44,038	30,105	20,636
Operating Segments [Member]
Net sales		219,863	193,484	161,651
Cost of sales		68,962	66,435	56,755
Gross profit		150,901	127,049	104,896
Selling expense		42,109	37,166	29,420
Marketing expense		4,628	3,888	3,501
Administrative expense		23,934	21,563	19,285
Finance expense		9,896	8,227	7,691
Management information systems expense		2,428	2,042	1,769
Research and development expense		3,431	2,738	1,895
Process engineering expense		2,938	3,632	3,051
Regulatory and clinical expense		9,281	10,596	8,348
Restructuring expense		0	485	3,107
Other income (expense), net*	[1]	8,218	6,607	6,193
Net income		$ 44,038	$ 30,105	$ 20,636

[1] Refer to the consolidated statements of operations for a listing of other income and expense.